UTHR Stock Analysis: Buy, Sell, or Hold?
UTHR - United Therapeutics Corp
$513.12
-7.88 (-1.51%)
âŧ
5d:
+2.68%
30d:
-3.1%
90d:
-9.32%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 05, 2026
0d
Smart Money Accumulation
Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →
Signal fired Aug 7, 2026 at $538.84 · last confirmed Aug 21, 2026
Strength: 7.7/10
Get Alerted When UTHR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: UTHR is fairly priced but lacks strong directional signals. At 1.5% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: UTHR is fairly priced but lacks strong directional signals. At 1.5% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$690.66
Based on 7.1% avg growth
INTRINSIC VALUE TODAY
$428.84
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 17.1x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: UTHR is currently trading at $513.12, which is considered slightly low relative to its 30-day fair value range of $513.09 to $532.64. The stock's valuation (Forward PE: 17.9) is in line with its historical norms (17.1). At these levels, the market is pricing in 1.5% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, UTHR is in a strong downtrend. Immediate support is located at $494.35, while resistance sits at $540.56.
Market Sentiment: The stock scores a mixed 42/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $664.33 (+29.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, UTHR is in a strong downtrend. Immediate support is located at $494.35, while resistance sits at $540.56.
Market Sentiment: The stock scores a mixed 42/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $664.33 (+29.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$513.09 -
$532.64
Company Quality Score
48/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
84.2%
Protect Your Profits
Holding UTHR? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (42/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 29.5% below Wall St target ($664.33)
- NEUTRAL: Market pricing in 1.5% annual earnings growth - fairly valued
- WARNING: Composite score 48/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$513.09 -
$532.64
Current vs Trading Range
SLIGHTLY LOW
Expected Move (7 Days)
Âą$23.58
(4.6%)
Support & Resistance Levels
Support Level
$494.35
Resistance Level
$540.56
Current Trend
Strong Downtrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
17.88
Wall Street Target
$664.33
(+29.5%)
Revenue Growth (YoY)
-1.9%
Earnings Growth (YoY)
13.4%
Profit Margin
41.6%
Valuation Premium vs History
+1.5% premium
PE vs Historical
17.9 vs 17.1
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+1.5%
(market-implied from PE analysis)
1-Year Target
$520.82
(+2%)
2-Year Target
$528.63
(+3%)
3-Year Target
$536.56
(+5%)
3-Yr Target (if PE normalizes)
(PE: 18â17)
PE COMPRESSION
$513.06
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.1, Growth: 10.2%)
$770.25
(+50%)
Base:
(SPY PE: 17.9, Growth: 10.2%)
$686.32
(+34%)
Bear:
(PE: 15.2, Growth: 10.2%)
$583.38
(+14%)
đ
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (19x PE), but valuation improves significantly next year (18x PE) as earnings recover.
Trailing PE: 18.67 | Current EPS (TTM): $27.90
Bull Case
$589.39
(+15%)
Analyst growth 2.8%, PE expands to 20.5
Base Case
$535.81
(+4%)
Market implied 2.8%, PE stable at 18.7
Bear Case
$354.28
(-31%)
Severe decline -20.0%, PE contracts to 15.9
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: August 23, 2026 7:04 AM ET
Data refreshes hourly during market hours. Next update: 8:04 AM
Data refreshes hourly during market hours. Next update: 8:04 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is UTHR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
20
Sells
Net
INSIDERS SELLING
Recent Transactions
Christopher Patusky
SELL
2910 shares
2026-04-24
James Edgemond
SELL
9636 shares
2026-04-23
James Edgemond
SELL
364 shares
2026-04-22
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences IâĻ |
STRONG BUY
25 analysts |
$212 | 67 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$107 | 56 HOLD |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$101 | 43 HOLD |
|
LQDA
Liquidia Technologies Inc |
STRONG BUY
10 analysts |
$108 | 55 HOLD |
|
BCRX
BioCryst PharmaceuticalsâĻ |
STRONG BUY
12 analysts |
$21 | 42 HOLD |
Advanced UTHR Option Strategies
Professional options setups generated by AI based on today's UTHR price and gamma walls.
